These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 10763147)
1. Cysteine proteinases and their inhibitors in extracellular fluids: markers for diagnosis and prognosis in cancer. Kos J; Werle B; Lah T; Brunner N Int J Biol Markers; 2000; 15(1):84-9. PubMed ID: 10763147 [TBL] [Abstract][Full Text] [Related]
2. Cysteine proteinases and their endogenous inhibitors: target proteins for prognosis, diagnosis and therapy in cancer (review). Kos J; Lah TT Oncol Rep; 1998; 5(6):1349-61. PubMed ID: 9769367 [TBL] [Abstract][Full Text] [Related]
3. Cathepsins B, H, and L and their inhibitors stefin A and cystatin C in sera of melanoma patients. Kos J; Stabuc B; Schweiger A; Krasovec M; Cimerman N; Kopitar-Jerala N; Vrhovec I Clin Cancer Res; 1997 Oct; 3(10):1815-22. PubMed ID: 9815568 [TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of cysteine proteinases cathepsins B and L and their endogenous inhibitors stefins A and B in patients with squamous cell carcinoma of the head and neck. Strojan P; Budihna M; Smid L; Svetic B; Vrhovec I; Kos J; Skrk J Clin Cancer Res; 2000 Mar; 6(3):1052-62. PubMed ID: 10741734 [TBL] [Abstract][Full Text] [Related]
5. Prognostic value of cathepsins B, H, L, D and their endogenous inhibitors stefins A and B in head and neck carcinoma. Budihna M; Strojan P; Smid L; Skrk J; Vrhovec I; Zupevc A; Rudolf Z; Zargi M; Krasovec M; Svetic B; Kopitar-Jerala N; Kos J Biol Chem Hoppe Seyler; 1996 Jun; 377(6):385-90. PubMed ID: 8839984 [TBL] [Abstract][Full Text] [Related]
6. Comparison of potential biological markers cathepsin B, cathepsin L, stefin A and stefin B with urokinase and plasminogen activator inhibitor-1 and clinicopathological data of breast carcinoma patients. Levicar N; Kos J; Blejec A; Golouh R; Vrhovec I; Frkovic-Grazio S; Lah TT Cancer Detect Prev; 2002; 26(1):42-9. PubMed ID: 12088202 [TBL] [Abstract][Full Text] [Related]
7. Cathepsins B and L are markers for clinically invasive types of meningiomas. Strojnik T; Zidanik B; Kos J; Lah TT Neurosurgery; 2001 Mar; 48(3):598-605. PubMed ID: 11270551 [TBL] [Abstract][Full Text] [Related]
8. Cysteine proteinases in cancer progression and their clinical relevance for prognosis. Lah TT; Kos J Biol Chem; 1998 Feb; 379(2):125-30. PubMed ID: 9524063 [TBL] [Abstract][Full Text] [Related]
9. Clinical and experimental studies of cysteine cathepsins and their inhibitors in human brain tumors. Lah TT; Strojnik T; Levicar N; Bervar A; Zajc I; Pilkington G; Kos J Int J Biol Markers; 2000; 15(1):90-3. PubMed ID: 10763148 [No Abstract] [Full Text] [Related]
10. Cysteine proteinases and cystatin C in bronchoalveolar lavage fluid from subjects with subclinical emphysema. Takeyabu K; Betsuyaku T; Nishimura M; Yoshioka A; Tanino M; Miyamoto K; Kawakami Y Eur Respir J; 1998 Nov; 12(5):1033-9. PubMed ID: 9863993 [TBL] [Abstract][Full Text] [Related]
11. Prognostic value of cathepsins B, D and steffins A and B in laryngeal carcinoma. Smid L; Strojan P; Budihna M; Skrk J; Vrhovec I; Zargi M; Kos J Eur Arch Otorhinolaryngol; 1997; 254 Suppl 1():S150-3. PubMed ID: 9065652 [TBL] [Abstract][Full Text] [Related]
12. Matrigel influences morphology and cathepsin B distribution of prostate cancer PC3 cells. Gopal P; Rehman RU; Chadha KS; Qiu M; Colella R Oncol Rep; 2006 Aug; 16(2):313-20. PubMed ID: 16820909 [TBL] [Abstract][Full Text] [Related]
13. Identification and discrimination of extracellularly active cathepsins B and L in high-invasive melanoma cells. Klose A; Zigrino P; Dennhöfer R; Mauch C; Hunzelmann N Anal Biochem; 2006 Jun; 353(1):57-62. PubMed ID: 16620747 [TBL] [Abstract][Full Text] [Related]
14. Human cysteine proteinases and their protein inhibitors stefins, cystatins and kininogens. Turk V; Brzin J; Kotnik M; Lenarcic B; Popović T; Ritonja A; Trstenjak M; Begić-Odobasić L; Machleidt W Biomed Biochim Acta; 1986; 45(11-12):1375-84. PubMed ID: 3495261 [TBL] [Abstract][Full Text] [Related]
15. Toward understanding recurrent meningioma: the potential role of lysosomal cysteine proteases and their inhibitors. Lah TT; Nanni I; Trinkaus M; Metellus P; Dussert C; De Ridder L; Rajcević U; Blejec A; Martin PM J Neurosurg; 2010 May; 112(5):940-50. PubMed ID: 19747051 [TBL] [Abstract][Full Text] [Related]
16. Cathepsins B and L and their inhibitors stefin B and cystatin C as markers for malignant progression of benign meningiomas. Trinkaus M; Vranic A; Dolenc VV; Lah TT Int J Biol Markers; 2005; 20(1):50-9. PubMed ID: 15832773 [TBL] [Abstract][Full Text] [Related]
17. Cathepsin expression in oral squamous cell carcinoma: relationship with clinicopathologic factors. Kawasaki G; Kato Y; Mizuno A Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2002 Apr; 93(4):446-54. PubMed ID: 12029284 [TBL] [Abstract][Full Text] [Related]
18. Assessment of cathepsin L activity by use of the inhibitor CA-074 compared to cathepsin B activity in human lung tumor tissue. Werle B; Ebert W; Klein W; Spiess E Biol Chem Hoppe Seyler; 1995 Mar; 376(3):157-64. PubMed ID: 7612192 [TBL] [Abstract][Full Text] [Related]
19. The expression and function of cystatin C and cathepsin B and cathepsin L during mouse embryo implantation and placentation. Afonso S; Romagnano L; Babiarz B Development; 1997 Sep; 124(17):3415-25. PubMed ID: 9310336 [TBL] [Abstract][Full Text] [Related]
20. Matrix metalloproteinases, but not cathepsins B, H, and L or their inhibitors in peripheral blood of patients with rheumatoid arthritis are potentially useful markers of disease activity. Keyszer G; Lambiri I; Keysser M; Keysser C; Nagel R; Burmester GR; Jung K Z Rheumatol; 1998 Dec; 57(6):392-8. PubMed ID: 10025098 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]